EUDA Enters into Convertible Loan Agreement with Shenzhen Inno, Further Expanding Stem Cell Therapy Platform
Rhea-AI Summary
EUDA (NASDAQ: EUDA) said its subsidiary EUDA Health entered a convertible loan agreement with Shenzhen Inno on Jan 13, 2026 to fund a cGMP facility upgrade in Shenzhen. EUDA expects to invest up to RMB 6 million in two tranches (RMB 1 million initial; RMB 5 million conditional), subject to due diligence, regulatory approvals and definitive documentation. The note carries an expected 6% per annum interest, payable semi-annually, and is convertible into equity or redeemable with accrued interest if not converted.
The deal is intended to anchor EUDA’s China regenerative medicine platform and support future expansion.
Positive
- Up to RMB 6 million investment into Shenzhen Inno
- Funds target cGMP facility upgrade in Shenzhen
- Convertible note provides equity optionality for EUDA
- 6% per annum interest, payable semi-annually
Negative
- Second tranche of RMB 5 million conditional on approvals and due diligence
- Conversion terms and resulting ownership percentage not yet determined
- Investment subject to regulatory approvals, creating execution risk
News Market Reaction
On the day this news was published, EUDA declined 13.93%, reflecting a significant negative market reaction. Argus tracked a peak move of +16.0% during that session. Argus tracked a trough of -28.8% from its starting point during tracking. Our momentum scanner triggered 40 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $18M from the company's valuation, bringing the market cap to $113M at that time. Trading volume was exceptionally heavy at 9.1x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
EUDA gained 5.63% while peers showed mixed moves; scanner only flagged OMH moving down, reinforcing that this looks stock-specific rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 07 | Warrant amendment | Neutral | +5.7% | Amended Streeterville warrant terms, lowering exercise and forced exercise prices. |
| Dec 30 | Stem cell platform | Positive | +0.0% | Launch of nationwide stem cell extraction and cryostorage platform in China. |
| Dec 29 | Product upgrade | Positive | -4.5% | Announcement of upgraded EUDA Helixé 2.0 longevity supplement launch. |
| Dec 23 | Clinic launch | Positive | +41.2% | Launch of comprehensive stem cell therapy platform and first Shenzhen clinic. |
| Dec 22 | Token integration | Neutral | -51.4% | Integration of QB utility token into EUDA’s digital health and rewards platform. |
Recent EUDA news has produced volatile and often mixed price reactions, with some strategic stem cell announcements aligning with sharp gains but several product and platform launches seeing muted or negative follow-through.
Over the last few weeks, EUDA has issued several strategy-focused updates. On Dec 23, 2025, launch of a comprehensive stem cell platform and first Shenzhen clinic saw a 41.18% move, while the nationwide stem cell platform announcement on Dec 30, 2025 had a 0% reaction. Token integration on Dec 22, 2025 coincided with a -51.43% move. The current Shenzhen Inno convertible loan deepens a stem cell partnership already highlighted in these prior releases.
Market Pulse Summary
The stock dropped -13.9% in the session following this news. A negative reaction despite positive partnership news would fit EUDA’s history of mixed responses to strategic updates. Prior initiatives, including product launches and digital-token integration, sometimes coincided with sharp declines even when narratives were constructive. With shares below the 200-day MA of 2.92, past patterns suggest that sentiment around financing structures and execution risks has mattered more than headline tone.
Key Terms
convertible loan agreement financial
convertible loan note financial
cGMP technical
autologous cellular therapeutics medical
natural killer cell medical
gamma delta T cell medical
mesenchymal stem cell medical
induced pluripotent stem cell medical
AI-generated analysis. Not financial advice.
SINGAPORE, Jan. 13, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore based non-invasive healthcare provider in Asia focused on Singapore, Malaysia and China, today announced that its wholly owned subsidiary, EUDA Health Pte. Ltd. (“EUDA Health”), has entered into a convertible loan agreement with Shenzhen Inno Immune Co., Ltd. (“Shenzhen Inno”), a developer of autologous cellular therapeutics and customised medicines for a wide range of diseases in China.
Strategic Investment and Facility Expansion Plan
Under the terms of the agreement, EUDA expects to invest up to RMB 6 million in two tranches, consisting of an initial tranche of RMB 1 million and a second tranche of RMB 5 million, subject to the completion of due diligence, regulatory approvals, and execution of definitive agreements.
Shenzhen Inno will deploy the capital to upgrade its cGMP facility in Shenzhen to create a state-of-the-art production and innovation center for stem cell treatments. The facility is expected to serve as a core technology and operating hub for EUDA’s China strategy, anchoring EUDA’s regenerative medicine capabilities, supporting international collaborations, and providing a replicable platform for expansion into additional cities and markets.
The investment is structured as a convertible loan note that provides the optionality for EUDA to convert into equity interest in Shenzhen Inno, with the resulting ownership percentage to be determined at the time of conversion based on valuation and definitive documentation. The convertible loan note is expected to carry an interest rate of
Shenzhen Inno operates a stem cell technology and therapy platform focused on advanced human cell processing, quality controlled cell culture, precision biological workflows and regulated laboratory operations supporting natural killer cell, gamma delta T cell, cytokine induced killer cell, mesenchymal stem cell, induced pluripotent stem cell and organoid based programs. The platform integrates biological processing infrastructure, quality and compliance systems, and scalable operating processes designed to support both clinical and research applications.
Shenzhen Inno – Strong Institutional Backing
In August 2017, HSG Capital Group (“HSG”), formerly known as Sequoia Capital China, a leading international venture capital and private equity firm, strategically invested approximately US
Mr Alfred Lim, Chief Executive Officer of EUDA, commented:
“This agreement reflects our disciplined approach to building long-term stem cell therapy platforms. By supporting the upgrade and expansion of a high-quality platform using a phased and flexible investment structure, we can validate execution, align our strategies, and create the foundation for deeper ownership and integration over time. This positions EUDA not only as a healthcare provider, but as a vertically integrated platform with technology, infrastructure and operational depth.”
About EUDA Health Holdings Limited
EUDA Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based leading non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China. The Company aims to become a market leader in non-invasive and preventive healthcare, with a strategic focus on the fast-growing longevity sector. Our mission is to address the evolving healthcare needs of over 1.8 billion people across the region which is experiencing significant demographic shifts as more than
Forward-Looking Statements
This document may contain forward-looking statements regarding risks and uncertainties. These statements usually use forward-looking words, such as the words “estimates,” “projected,” “expects,” “envisions,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions). These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside EUDA’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. You should not overly rely on forward-looking statements that are only applicable to the date of publication of this document. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Christensen Advisory
Christian Arnell
Phone: + 852 9040 0621
Email: christian.arnell@christensencomms.com
FAQ
What did EUDA (NASDAQ: EUDA) announce on January 13, 2026?
How is the RMB 6 million investment structured for EUDA (EUDA)?
What are the key financial terms of the Shenzhen Inno convertible note for EUDA (EUDA)?
What will the Shenzhen Inno funds be used for under EUDA's (EUDA) deal?
Does EUDA (EUDA) immediately receive equity in Shenzhen Inno from this deal?
What are the main risks to EUDA (EUDA) completing the full investment?
